Analyst Rating Update on Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (NYSE:EW) : 17 analysts are covering Edwards Lifesciences Corporation (NYSE:EW) and their average rating on the stock is 1.68, which is read as a Buy. 10 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. Edwards Lifesciences Corporation (NYSE:EW) also receives 2 more Buy recommendations from analysts who believe that the stock will do well going forward. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Edwards Lifesciences Corporation (NYSE:EW) : 14 Wall Street analysts covering Edwards Lifesciences Corporation (NYSE:EW) believe that the average level the stock could reach for the short term is $117.14. The maximum price target given is $132 and the minimum target for short term is around $100, hence the standard deviation is calculated at $9.26.

For the current week, the company shares have a recommendation consensus of Buy. Also, Guggenheim Securities initiates coverage on Edwards Lifesciences Corporation (NYSE:EW) . Analysts at the Guggenheim Securities have a current rating of Neutral on the shares. The rating by the firm was issued on June 9, 2016.

Edwards Lifesciences Corporation (NYSE:EW): stock turned positive on Tuesday. Though the stock opened at $95.13, the bulls momentum made the stock top out at $95.38 level for the day. The stock recorded a low of $94.126 and closed the trading day at $94.97, in the green by 0.47%. The total traded volume for the day was 2,087,326. The stock had closed at $94.53 in the previous days trading.

In an insider trading activity, Mussallem Michael A, director officer (Chairman & CEO) of Edwards Lifesciences Corp, unloaded 49,100 shares at an average price of $102.25 on June 8, 2016. The total amount of the transaction was worth $5,020,475, according to the disclosed information with the Securities and Exchange Commission in a Form 4 filing.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patients diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patients cardiovascular function in the hospital setting. Patients in the hospital setting, including high-risk patients in the operating room or intensive care unit, are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Companys products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy, Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.